Stockscreener 앱 받기
8.49
3.52%
-0.31
시간 외 거래:
8.35
-0.14
-1.65%
전일 마감가:
$8.80
열려 있는:
$8.78
하루 거래량:
541.05K
Relative Volume:
0.63
시가총액:
$308.12M
수익:
$10.00M
순이익/손실:
$-75.99M
주가수익비율:
-3.5563
EPS:
-2.3873
순현금흐름:
$-80.36M
1주 성능:
-12.02%
1개월 성능:
-38.43%
6개월 성능:
-63.29%
1년 성능:
+0.00%
1일 변동 폭
$8.33
$8.78
1주일 범위
$8.25
$9.865
52주 변동 폭
$8.25
$33.20
Evommune Inc Stock (EVMN) Company Profile
명칭
Evommune Inc
전화
(650) 223-7745
주소
1891 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
8.49 | 308.12M | 10.00M | -75.99M | -80.36M | -2.3873 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-07 | 재개 | Oppenheimer | Outperform |
| 2026-01-22 | 개시 | Oppenheimer | Outperform |
| 2026-01-08 | 개시 | Raymond James | Strong Buy |
| 2026-01-06 | 개시 | H.C. Wainwright | Buy |
| 2025-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-12-01 | 개시 | Evercore ISI | Outperform |
| 2025-12-01 | 개시 | Leerink Partners | Outperform |
| 2025-12-01 | 개시 | Morgan Stanley | Overweight |
| 2025-12-01 | 개시 | William Blair | Outperform |
모두보기
Evommune Inc 주식(EVMN)의 최신 뉴스
Evommune (EVMN) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress - biospace.com
Evommune Reports Phase 2a EVO301 Atopic Dermatitis Data at EADV 2026 via 8-K Filing - Kalkine Media
Evommune to present phase 2a atopic dermatitis data at EADV By Investing.com - Investing.com Nigeria
Evommune (EVMN) Edges Higher: Shares Gain 1.59% to $9.60 as Buyers Hold SupportCup and Handle - siam.in
Evommune: Pipeline Reset After EVO756 Failure, All Eyes On EVO301 (NYSE:EVMN) - Seeking Alpha
Analysts Have Conflicting Sentiments on These NA Companies: Evommune, Inc. (EVMN) and Douglas AG (OtherDOUDF) - The Globe and Mail
Cantor Fitzgerald reiterates Evommune stock rating at Overweight - Investing.com
Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline? - finance.yahoo.com
EVMN: Advancing novel therapies in atopic dermatitis and migraine, with strong funding and pipeline momentum - TradingView
Evommune Releases Updated Corporate Presentation Compliant with Regulation FD - Kalkine Media
Form 8K Evommune Inc For: 15 September By Investing.com - Investing.com India
Evommune posts updated corporate presentation outlining pipeline progress, cash runway and 2027–2028 milestones - TradingView
Evommune（NYSE: EVMN）が現金を賢明に活用することを期待しています。 - Moomoo
Analysts Offer Insights on NA Companies: Chime Financial, Inc. Class A (CHYM), ServiceTitan, Inc. Class A (TTAN) and Evommune, Inc. (EVMN) - The Globe and Mail
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), Inhibrx Biosciences Inc (INBX) and Circle Internet Group, Inc. Class A (CRCL) - The Globe and Mail
Evommune stock maintains Buy rating despite trial setback By Investing.com - Investing.com Nigeria
RBC cuts Evommune stock price target on drug trial setback By Investing.com - Investing.com Australia
Evommune Scraps Itch Drug After Second Phase 2 Failure, Stock Slides 18% - finance.biggo.com
EVMN Maintains Rating by Leerink Partners -- Price Target Lowered to $22 - GuruFocus
Evommune Drops AD Program Following Phase 2B Trial Failure - The Dermatology Digest
Why this company's stock took a hit just 10 months after its IPO - The Business Journals
Evommune’s EVO-756 fails dermatitis study; focus on migraine - BioWorld News
Stifel reiterates Evommune stock rating after phase 2b trial miss By Investing.com - Investing.com Nigeria
Stifel reiterates Evommune stock rating after phase 2b trial miss - Investing.com
Evommune Reports EVO756 Phase 2b Trial Failure in Atopic Dermatitis, Halts Development for This Indication - Kalkine Media
Evommune (NYSE:EVMN) Price Target Lowered to $21.00 at Royal Bank Of Canada - MarketBeat
RBC cuts Evommune stock price target on drug trial setback - Investing.com India
Why is Evommune stock plunging today? By Investing.com - Investing.com Australia
Evommune's (EVMN) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Evommune stock maintains Buy rating despite trial setback - Investing.com
Evommune Halts Atopic Dermatitis Program Following Trial Failure - Benzinga
Why is Evommune stock sliding 13% today? - Investing.com
RBC Cuts Price Target on Evommune to $21 From $29, Keeps Outperform, Speculative Risk - marketscreener.com
Why is Evommune stock sliding 13% today? By Investing.com - Investing.com Canada
Why is Evommune stock tumbling today? By Investing.com - Investing.com Canada
Evommune's EVO756 suffers second Phase IIb setback in two months with AD miss - AllSci
Evommune’s EVO756 fails phase 2b trial in atopic dermatitis By Investing.com - Investing.com India
Evommune stock tumbles after trial misses primary endpoint By Investing.com - Investing.com South Africa
Evommune stock tumbles after trial misses primary endpoint - investing.com
Why Is EVMN Stock Down 13% After-Hours? - Yahoo Finance
Evommune scraps eczema drug after trial miss, shares plunge - Reuters
Evommune’s EVO756 fails phase 2b trial in atopic dermatitis - investing.com
Why is Evommune stock plunging today? - investing.com
Evommune Inc (EVMN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):